Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized multicenter study of THR-687 versus aflibercept for diabetic macular edema
MOH_2022-03-13_010348Phase 2Completed
- Sponsor
- Oxurion
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of THR-687 in diabetic macular edema (DME) (2 arms), sponsored by Oxurion. Primary endpoint: Difference in treatment effect between THR-687 and aflibercept. Started Jan 2022; status: completed.
02
Drugs
THR-687
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2022-03-13_010348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-13_010348.